Skip to main content
. 2015 Apr 2;17(12):1568–1577. doi: 10.1093/neuonc/nov058

Fig. 3.

Fig. 3.

Antitumor effect of MV-GFP. To model primary disease BT-12 (A) and BT-16 (C) Atypical teratoid rhabdoid tumors (AT/RTs) were established in the right frontal lobe of female athymic nude mice. Seven days after tumor implantation, the mice received a total of 5 × 105 pfu of MV-GFP or the same dose of UV-inactivated MV-GFP. In both xenograft models, mice treated with MV-GFP had significantly longer survival than mice treated with UV-inactivated MV-GFP (P < .0001). Four MV–GFP-treated animals implanted with BT-12 in the frontal lobe remained alive at the experimental endpoint (100 days). To model disseminated disease, BT-12 (B) and BT-16 (D) cells were injected into the right lateral ventricle of female athymic nude mice. Three days post tumor implantation the mice received a total of 5 × 105 pfu of MV-GFP or the same dose of UV–MV-GFP injected directly into the right lateral ventricle. Mice treated with MV-GFP had significantly longer survival than mice treated with UV-MV-GFP (P < .0001).